Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Vertex Pharmaceuticals Incorporated patents


Recent patent applications related to Vertex Pharmaceuticals Incorporated. Vertex Pharmaceuticals Incorporated is listed as an Agent/Assignee. Note: Vertex Pharmaceuticals Incorporated may have other listings under different names/spellings. We're not affiliated with Vertex Pharmaceuticals Incorporated, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "V" | Vertex Pharmaceuticals Incorporated-related inventors


Dna-pk inhibitors

. . The present invention relates to compounds useful as inhibitors of dna-pk. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.. ... Vertex Pharmaceuticals Incorporated

Dna-pk inhibitors

The present invention relates to compounds useful as inhibitors of dna-pk. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.. ... Vertex Pharmaceuticals Incorporated

Modulators of atp-binding cassette transporters

. . . . . . Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of atp-binding cassette (“abc”) transporters or fragments thereof, including cystic fibrosis transmembrane conductance regulator (“cftr”). The present invention also relates to methods of treating abc transporter mediated diseases using compounds of the present invention.. ... Vertex Pharmaceuticals Incorporated

Dna-pk inhibitors

The present invention relates to compounds useful as inhibitors of dna-pk. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.. ... Vertex Pharmaceuticals Incorporated

Pharmaceutical compositions and administrations thereof

. . . . The present invention relates to pharmaceutical compositions comprising a compound of formula i in combination with one or both of a compound of formula ii and/or a compound of formula iii. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of cftr mediated diseases, particularly cystic fibrosis.. ... Vertex Pharmaceuticals Incorporated

Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

. . The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methypyridin-2-yl)benzoic acid (form i), pharmaceutical compositions thereof, and methods of treatment therewith.. . ... Vertex Pharmaceuticals Incorporated

Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway

. . . . . . . . . . . . The compounds of formula i, wherein the variables are as defined herein, and pharmaceutically acceptable salts thereof are useful as inhibitors of the par-2 signaling pathway. The compounds of formula i and pharmaceutically acceptable compositions comprising such compounds can be employed for treating various diseases, disorders, and conditions.. ... Vertex Pharmaceuticals Incorporated

Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

. . . . A pharmaceutical composition comprising compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a cftr mediated disease such as cystic fibrosis. Processes of preparing pharmaceutical compositions comprising compound 1 are also disclosed.. ... Vertex Pharmaceuticals Incorporated

Process of conducting high throughput testing high performance liquid chromatography

The present invention utilizes a high throughput testing (htt) method of high performance liquid chromatography (hplc) to validate samples of pharmaceutical compositions. In one embodiment, improved sample preparation techniques comprise adding the entire vial of a sample to a wide mouth disposable bottle, adding diluent, shaking overnight, and centrifuging.. ... Vertex Pharmaceuticals Incorporated

Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d] [1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarbox-amide and administration thereof

. . . . . . A pharmaceutical composition comprising compound 1, (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a cfr mediated disease such as cystic fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of compound 1 are also disclosed.. ... Vertex Pharmaceuticals Incorporated

Isoindolinone inhibitors of phosphatidylinositol 3-kinase

The present invention relates to compounds useful as inhibitors of pi3k, particularly of pi3kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.. ... Vertex Pharmaceuticals Incorporated

Dna-pk inhibitors

The present invention relates to compounds useful as inhibitors of dna-pk. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.. ... Vertex Pharmaceuticals Incorporated

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1), pharmaceutical compositions thereof and methods therewith.. . ... Vertex Pharmaceuticals Incorporated

Influenza a virus variants

The present invention relates to influenza a virus variants, particularly variants that are resistant to a polymerase inhibitors. Also provided are methods and compositions related to the influenza a virus variants. ... Vertex Pharmaceuticals Incorporated

07/20/17 / #20170204478

Influenza a virus variants

The present invention relates to influenza a virus variants, particularly variants that are resistant to a polymerase inhibitors. Also provided are methods and compositions related to the influenza a virus variants. ... Vertex Pharmaceuticals Incorporated

07/06/17 / #20170189389

Modulators of atp-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of atp-binding cassette (“abc”) transporters or fragments thereof, including cystic fibrosis transmembrane conductance regulator (“cftr”). The present invention also relates to methods of treating abc transporter mediated diseases using compounds of the present invention.. ... Vertex Pharmaceuticals Incorporated

04/20/17 / #20170107225

Heteroaryl derivatives as cftr modulators

The present invention relates to modulators of atp-binding cassette (“abc”) transporters or fragments thereof, including cystic fibrosis transmembrane conductance regulator (“cftc”), compositions thereof, and methods therewith. The present invention also relates to methods of treating abc transporter mediated diseases using such modulators.. ... Vertex Pharmaceuticals Incorporated

04/20/17 / #20170107206

Modulators of atp-binding cassette transporters

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of atp-binding cassette (“abc”) transporters or fragments thereof, including cystic fibrosis transmembrane conductance regulator (“cftr”). The present invention also relates to methods of treating abc transporter mediated diseases using compounds of the present invention.. ... Vertex Pharmaceuticals Incorporated

04/20/17 / #20170107205

Modulators of atp-binding cassette transporters

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of atp-binding cassette (“abc”) transporters or fragments thereof, including cystic fibrosis transmembrane conductance regulator (“cftr”). The present invention also relates to methods of treating abc transporter mediated diseases using compounds of the present invention.. ... Vertex Pharmaceuticals Incorporated

04/13/17 / #20170100340

Pharmaceutical composition and administrations thereof

. . The present invention relates to pharmaceutical compositions containing a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.. . ... Vertex Pharmaceuticals Incorporated

03/30/17 / #20170087144

Pharmaceutical composition and administrations thereof

. . The present invention relates to pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.. . ... Vertex Pharmaceuticals Incorporated

03/16/17 / #20170073315

Methods of regioselective synthesis of 2,4-disubstituted pyrimidines

The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.. . ... Vertex Pharmaceuticals Incorporated








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Vertex Pharmaceuticals Incorporated in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vertex Pharmaceuticals Incorporated with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###